Small Molecules for Precision Medicine

Learn More about Arqule

We are pursuing multiple programs in biomarker-defined oncology and rare disease indications

Targeted Approach to Cancer

Clinical Trials

Learn More

Research & Development

Product Pipeline

Explore

Targeted Approach To

Rare Diseases

Read More

News & Events

September 29, 2017
Proteus Syndrome Phase 1 Data Presentation
Watch Video »
August 13, 2018
ArQule Announces Publication of Preclinical Data for ARQ 531, a Reversible Inhibitor of Both Wild Type and Mutant BTK
Read More »
August 1, 2018
ArQule Reports Second Quarter 2018 Financial Results
Read More »

More News & Events »

arqule

© Copyright ArQule. All rights reserved. Terms of Use.